Revolutionising Diabetes Care

Improving diabetes care has the potential to transform individual health outcomes while strengthening the wellbeing of entire communities.
Picture: Associate Professor Neale Cohen

Revolutionising Diabetes Care

July 1, 2026
Improving diabetes care has the potential to transform individual health outcomes while strengthening the wellbeing of entire communities.
Read Transcript

The challenge

Diabetes is a significant health challenge in remote communities, where access to healthcare can be limited and health outcomes are often worse than in the broader population.

According to the Australian Institute of Health and Welfare, diabetes has a significant health and economic impact in Australia, costing Australia's health system more than $4 billion each year. In remote communities, the burden is even greater, increasing the risk of serious complications including heart disease, kidney disease and premature death.

Improving diabetes care has the potential to transform individual health outcomes while strengthening the wellbeing of entire communities.

Project overview 

Researchers are testing a new approach to diabetes care designed specifically for remote communities. The IMPROVE SUGAR study is a national cluster-randomised trial evaluating an intensive diabetes management model for Aboriginal and Torres Strait Islander adults living with inadequately controlled Type 2 diabetes. The model combines culturally appropriate care, intensive lifestyle support and treatment with tirzepatide, a once-weekly medication.

Across five states and ten communities, 260 participants will be divided into standard and intensive care groups. The trial aims to determine whether this approach can improve blood sugar control, reduce diabetes-related complications and provide a sustainable model of care that can be adopted more broadly across remote communities.

The role of philanthropy

Funding from Hearts & Minds, as nominated by TDM Growth Partners, has helped Baker Heart and Diabetes Institute undertake critical early-stage activities, including community engagement, research collaborations, ethics approvals, and the recruitment of staff and participants. The study is now underway, with Site Initiation Visits successfully completed at Bidgerdii Rockhampton and Blackwater. These milestones pave the way for participant recruitment and trial delivery across participating communities.

What this could unlock

This project has the potential to reshape diabetes care for Aboriginal and Torres Strait Islander people living in regional and remote Australia. By testing a more accessible and culturally appropriate model of care, the research could reduce complications, improve quality of life and support better long-term health outcomes. The findings will provide important evidence to guide future diabetes treatment and care in remote communities across Australia. Closing the gap in health outcomes and life expectancy is, and always has been, the driving force behind this work.

Funding support from Hearts & Minds, as nominated by Core Fund Manager, TDM Growth Partners. For further information visit Baker Hearts and Diabetes Institute. This content was last updated in July 2026.

The challenge

Diabetes is a significant health challenge in remote communities, where access to healthcare can be limited and health outcomes are often worse than in the broader population.

According to the Australian Institute of Health and Welfare, diabetes has a significant health and economic impact in Australia, costing Australia's health system more than $4 billion each year. In remote communities, the burden is even greater, increasing the risk of serious complications including heart disease, kidney disease and premature death.

Improving diabetes care has the potential to transform individual health outcomes while strengthening the wellbeing of entire communities.

Project overview 

Researchers are testing a new approach to diabetes care designed specifically for remote communities. The IMPROVE SUGAR study is a national cluster-randomised trial evaluating an intensive diabetes management model for Aboriginal and Torres Strait Islander adults living with inadequately controlled Type 2 diabetes. The model combines culturally appropriate care, intensive lifestyle support and treatment with tirzepatide, a once-weekly medication.

Across five states and ten communities, 260 participants will be divided into standard and intensive care groups. The trial aims to determine whether this approach can improve blood sugar control, reduce diabetes-related complications and provide a sustainable model of care that can be adopted more broadly across remote communities.

The role of philanthropy

Funding from Hearts & Minds, as nominated by TDM Growth Partners, has helped Baker Heart and Diabetes Institute undertake critical early-stage activities, including community engagement, research collaborations, ethics approvals, and the recruitment of staff and participants. The study is now underway, with Site Initiation Visits successfully completed at Bidgerdii Rockhampton and Blackwater. These milestones pave the way for participant recruitment and trial delivery across participating communities.

What this could unlock

This project has the potential to reshape diabetes care for Aboriginal and Torres Strait Islander people living in regional and remote Australia. By testing a more accessible and culturally appropriate model of care, the research could reduce complications, improve quality of life and support better long-term health outcomes. The findings will provide important evidence to guide future diabetes treatment and care in remote communities across Australia. Closing the gap in health outcomes and life expectancy is, and always has been, the driving force behind this work.

Funding support from Hearts & Minds, as nominated by Core Fund Manager, TDM Growth Partners. For further information visit Baker Hearts and Diabetes Institute. This content was last updated in July 2026.

Disclaimer: This material has been prepared by Hearts & Minds, published on July 1, 2026. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
February 14, 2023

Bringing Equity and Diversity to Genomic Medicine

Professor Daniel MacArthur, Director of the Centre for Population Genomics has big goals to bring equity and diversity into genomic medicine in Australia, something surprisingly inadequate presently.

Read More
September 6, 2022

VCCRI: 'Heart in a Box'

An Australian method of preserving donated hearts has boosted the number of successful transplants across the world, with new research demonstrating similar survival rates to traditional transplants.

Read More
February 24, 2022

Impact Video: Cerebral Palsy Alliance

This video features Professor Nadia Badawi AM, Professor Alistair McEwan, Paul Rayson and others discussing the incredible impact our partnership will have.

Read More
February 24, 2022

New Partnership with Cerebral Palsy Alliance

We’re excited to announce a new partnership with the Cerebral Palsy Alliance and are proud to be supporting this important research.

Read More
August 3, 2021

Australian breakthrough to stop heart arteries from clogging

Victor Chang scientist has led landmark research that has the potential to stop arteries of the heart from becoming clogged by targeting a particular gene.

Read More
October 12, 2020

Beneficiary Profile: Victor Chang

Cardiovascular disease is the number one cause of death globally and costs the Australian economy $12 billion each year. Every 12 minutes, one Australian dies from the disease. This is why the Victor Chang Cardiac Research Institute is dedicated to finding cures through their world class research.

Read More
September 23, 2020

Silent wave' of brain damage could follow pandemic

Australia urgently needs to prepare for a "silent wave" of COVID-19, which appears to be taking the form of long-term neurological side effects following infection with the virus.

Read More
September 8, 2020

Beneficiary Profile: Black Dog Institute

1 in 5 of us will experience symptoms of mental illness in any given year. In Australia that’s around 5 million people. And roughly 60% of these people won’t seek help. Learn what Black Dog is doing to create a mentally healthier world for everyone.

Read More
August 10, 2020

Beneficiary Profile: RPA Green Light

Emergency departments are the frontline of health care, with one in seven Australians seeking help from a hospital emergency department every year. Our medical staff depend on research findings to help inform their responses to urgent patient needs.

Read More
July 7, 2020

Beneficiary Profile: The Florey

Every year, 4.7 million Australians are diagnosed with one of the conditions that the Florey study. That's why they believe everyone has a stake in medical research.

Read More
June 9, 2020

Beneficiary Profile: Orygen

1 in 5 young people will have experienced a depressive episode by the time they are 18. With thanks to Cooper Investors and Hearts & Minds, we have been able to put youth mental health on the global agenda and progress our work in developing a global mental health framework.

Read More
November 22, 2019

Impact Video Series: Sydney Children's Hospital Foundation

We interviewed leading individuals from our beneficiaries to discuss the importance of medical research, their recent breakthroughs and the vital need for private funding.

Read More
May 29, 2019

Winning Hearts and Minds

Mark Nelson of Caledonia discusses his connection with the Florey Institute, one of our beneficiaries, and why he's involved with Hearts and Minds.

Read More
December 10, 2024

Professor Jane Butler: Sparking Hope for Spinal Cord Injuries

In this episode of the Hearts & Minds Podcast, we sit down with Professor Jane Butler to discuss her groundbreaking research into spinal cord injuries.

Read More
impact-podcasts
September 24, 2024

Asian Market Potential with Tom Naughton of Prusik

CIO Charlie Lanchester sits down with Tom Naughton, CIO of Prusik Investment Mgmt. Tom shares his investment philosophy, the opportunities and challenges in Asian markets, and how his 2023 conference stock pick, Swire Pacific (0019.HK), delivered an impressive 30% return.

Read More
investing
September 4, 2024

Building Hearts and Minds with Co-Founders Matthew Grounds and Guy Fowler

In this episode, co-founders Matthew Grounds AM and Guy Fowler OAM discuss their journey in building Hearts & Minds and its philanthropic model that has donated over $70 million to medical research.

Read More
investing
June 25, 2024

Navigating the Resource Sector with Jeremy Bond of Terra Capital

In this episode, we chat with Jeremy Bond, Founder of Terra Capital and HM1 Conference Fund Manager. Tune in for insights into the world of resource investments and the exciting opportunities that lie ahead.

Read More
investing
June 11, 2024

Prof. Nadia Badawi on Cerebral Palsy Breakthroughs and Neonatal Care

Dive deep into the groundbreaking work of Professor Nadia Badawi, an internationally recognised neonatologist and expert in Cerebral Palsy.

Read More
impact-podcasts
May 28, 2024

Investment Insights: Rikki Bannan on Top Picks and Trends

Join us for an engaging episode featuring Rikki Bannan, Portfolio Manager of IFM Investors and HM1 Conference Fund Manager. This episode explores Rikki's career journey, investment strategies, and her 2023 conference stock pick, Telix Pharmaceuticals (ASX.TLX).

Read More
investing
December 6, 2023

Peter Cooper talks building and instilling a culture of humility and excellence

In this episode, our guest is the renowned investor, Peter Cooper, founder and Chief Investment Officer of Cooper Investors (Core Fund Manager). A founding supporter of Hearts and Minds, Peter is a staunch advocate of our model and its philanthropic purpose, actively engaging in every facet of Hearts and Minds.

Read More
investing
November 28, 2023

Jun Bei Liu on her high conviction investment strategy

In this episode, HM1 Chief Investment Officer Charlie Lanchester is joined by Jun Bei Liu. Jun Bei is the Portfolio Manager of Tribeca’s Alpha Plus Fund and since taking over managing the Fund, she has quadrupled AUM.

Read More
investing
November 21, 2023

The world of rare genetic disease research

In this episode, we speak to Associate Professor Gina Ravenscroft. Gina is an Associate Professor in Neurogenetics at the Harry Perkins Institute of Medical Research in Perth. Her research interests are in rare genetic diseases, with a particular focus on neurogenetic diseases in babies and children.

Read More
impact-podcasts
November 14, 2023

Learn what makes a high conviction investment and how to avoid short-term noise

In this episode, our Core Fund Manager Magellan shares how they select top stocks for the HM1 portfolio.

Read More
investing
November 7, 2023

Delve into the world of kids critical care and trauma research

In thie episode, we are joined by Dr. Marino Festa, or Rino for short. He is the Medical Director of NSW Kids ECMO Referral Service and a senior specialist in Paediatric Intensive Care at Children’s Hospital at Westmead.

Read More
impact-podcasts
October 31, 2023

Where Regal's Phil King is searching for opportunities

HM1's CIO, Charlie Lanchester, talks to Phil King of Regal Funds about his passion for stocks, his ongoing search for opportunities, and some of the sectors he’s excited by right now. Phil King of Regal Funds, has been a tremendous supporter of Hearts & Minds since the beginning.

Read More
investing
October 24, 2023

Preventing recurrent miscarriages and birth defects

In this episode, CEO Paul Rayson is joined by renowned biomedical researcher Professor Sally Dunwoodie. Prof. Dunwoodie's groundbreaking work has revolutionised clinical practices and enabled genetic diagnostic tests worldwide. In 2017, her team achieved a double breakthrough with the potential to prevent recurrent miscarriages and various birth defects.

Read More
impact-podcasts
October 17, 2023

Nick Griffin on how he finds global winners

In this episode, CIO Charlie Lanchester chats with Nick Griffin, the founding partner and CIO of Munro Partners, one of HM1's Core Fund Managers. They go over his career to date, reflect on the lessons he’s learned, and trace the decisions that led to him starting Munro.

Read More
investing
October 10, 2023

How A/Prof Matt Call is teaching our body to kill cancer

In this episode, CEO Paul Rayson is joined by WEHI’s Associate Professor Matt Call to talk about his incredible research. Matt’s team teaches and trains the body's own immune cells to target and kill cancer cells.

Read More
impact-podcasts

No results found.

Please try a different search keyword or filter.